Skip to main content
Year archive

BerGenBio — 2022 filings

All 91 regulatory filings released by BerGenBio (BGBIO) in 2022, sourced directly from the official regulator.

91 Filings
2022 Period
2022 filings (91)
Filing Released Lang
Financial calendar
Report Publication Announcement
2022-12-21 English
BerGenBio to present at DNB's Nordic Healthcare Conference
Report Publication Announcement
2022-12-08 English
BerGenBio to present at DNB's Nordic Healthcare Conference
Report Publication Announcement
2022-12-08 English
BerGenBio ASA: Grant of share options
Director's Dealing
2022-11-21 English
BerGenBio ASA: Grant of share options
Remuneration Information
2022-11-21 English
BerGenBio reports third quarter 2022 financial results and provides business update
Interim / Quarterly Report Q3 2022
2022-11-15 English
BerGenBio reports third quarter 2022 financial results and provides business update
Earnings Release Q3 2022
2022-11-15 English
BerGenBio ASA: Invitation to third quarter 2022 results webcast
Report Publication Announcement
2022-11-08 English
BerGenBio ASA: Invitation to third quarter 2022 results webcast
Report Publication Announcement
2022-11-08 English
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS
Capital/Financing Update
2022-10-25 English
BerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva AS
Capital/Financing Update
2022-10-25 English
BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
Regulatory Filings
2022-10-11 English
BerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 Mutations
Regulatory Filings
2022-10-11 English
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
Regulatory Filings
2022-09-27 English
BERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTS
Regulatory Filings
2022-09-27 English
BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference
Report Publication Announcement
2022-09-07 English
BerGenBio to Present at Pareto Securities' 13th Annual Healthcare Conference
Regulatory Filings
2022-09-07 English
BerGenBio reports second quarter and half year 2022 financial results and provides business update
Interim / Quarterly Report H1 2022
2022-08-23 English
BerGenBio reports second quarter and half year 2022 financial results and provides business update
Earnings Release H1 2022
2022-08-23 English
BerGenBio reports second quarter and half year 2022 financial results and provides business update
Earnings Release H1 2022
2022-08-23 English
BERGENBIO ASA: Invitation to second quarter and half year 2022 results webcast
Report Publication Announcement
2022-08-09 English
BERGENBIO ASA: Invitation to second quarter and half year 2022 results webcast
Report Publication Announcement
2022-08-09 English
BerGenBio - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-06-16 English
BerGenBio - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-06-16 English
BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022
Investor Presentation
2022-06-06 English
BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022
Environmental & Social Information
2022-06-06 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
Interim / Quarterly Report Q1 2022
2022-05-24 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
Earnings Release Q1 2022
2022-05-24 English
BERGENBIO ASA: RESULTS FOR THE FIRST QUARTER 2022
Earnings Release Q1 2022
2022-05-24 English
BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST
Report Publication Announcement
2022-05-18 English
BERGENBIO ASA: INVITATION TO FIRST QUARTER 2022 RESULTS WEBCAST
Report Publication Announcement
2022-05-18 English
BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT
Regulatory Filings
2022-05-16 English
BERGENBIO TO PRESENT AT ABG SUNDAL COLLIER LIFE SCIENCE SUMMIT
Report Publication Announcement
2022-05-16 English
BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
Investor Presentation
2022-05-04 English
BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19
Regulatory Filings
2022-05-04 English
BerGenBio ASA: Minutes from the Annual General Meeting
AGM Information
2022-04-28 Norwegian
BerGenBio ASA: Minutes from the Annual General Meeting
AGM Information
2022-04-28 English
BERGENBIO TO PRESENT AT ARCTIC SECURITIES BIOTECH WEBINAR
Report Publication Announcement
2022-04-26 English
BERGENBIO TO PRESENT AT ARCTIC SECURITIES BIOTECH WEBINAR
Regulatory Filings
2022-04-26 English
BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET
Regulatory Filings
2022-04-26 English
BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS - PRIMARY EFFICACY ENDPOINT MET
Regulatory Filings
2022-04-26 English
BERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022
Regulatory Filings
2022-04-25 English
BERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022
Regulatory Filings
2022-04-25 English
BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer
Board/Management Information
2022-04-11 English
BerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical Officer
Board/Management Information
2022-04-11 English
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2022-04-07 English
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2022-04-07 Norwegian
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2022-04-07 English
BERGENBIO ASA: NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2022-04-07 English
BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021
Annual Report FY 2021
2022-04-07 English
BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021
Annual Report (ESEF) FY 2021
2022-04-07 English
BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021
Report Publication Announcement
2022-04-07 English
BERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021
Report Publication Announcement
2022-04-07 English
BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION
Regulatory Filings
2022-03-17 English
BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION
Regulatory Filings
2022-03-17 English
BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR
Regulatory Filings
2022-03-17 English
BERGENBIO TO PRESENT AT CARNEGIE VIRTUAL NORDIC HEALTHCARE SEMINAR
Regulatory Filings
2022-03-17 English
BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION
Regulatory Filings
2022-03-17 English
BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION
Regulatory Filings
2022-03-17 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2022-02-22 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2022-02-22 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2022-02-16 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2022-02-16 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
Interim / Quarterly Report Q4 2021
2022-02-16 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
Earnings Release FY 2021
2022-02-16 English
BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
Earnings Release FY 2021
2022-02-16 English
BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST
Report Publication Announcement
2022-02-08 Norwegian
BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST
Report Publication Announcement
2022-02-08 English
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2022-02-03 Norwegian
BerGenBio ASA: Share capital increase
Share Issue/Capital Change
2022-02-03 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2022-01-27 English
BerGenBio ASA: Increase of share capital, exercise of share options
Share Issue/Capital Change
2022-01-27 English
BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
Regulatory Filings
2022-01-27 English
BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
Regulatory Filings
2022-01-27 English
BerGenBio - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-01-10 English
BerGenBio - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-01-10 English
BerGenBio - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-01-10 English
BerGenBio - Mandatory notification of trade by Primary Insiders
Director's Dealing
2022-01-07 English
BerGenBio - Mandatory notification of trade by Primary Insiders
Director's Dealing
2022-01-07 English
BerGenBio - Mandatory notification of trade by Primary Insiders
Director's Dealing
2022-01-07 English
BERGENBIO - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-01-07 Norwegian
BERGENBIO - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-01-07 English
BERGENBIO - Mandatory notification of trade by Primary Insider
Director's Dealing
2022-01-07 English
BERGENBIO APPOINTS ANDERS TULLGREN AS CHAIRMAN OF BOARD
Board/Management Information
2022-01-06 English
BERGENBIO APPOINTS ANDERS TULLGREN AS CHAIRMAN OF BOARD
Board/Management Information
2022-01-06 English
BerGenBio ASA: Extraordinary General Meeting held
AGM Information
2022-01-06 Norwegian
BerGenBio ASA: Extraordinary General Meeting held
AGM Information
2022-01-06 English
BerGenBio ASA: Extraordinary General Meeting held
AGM Information
2022-01-06 English
BerGenBio - Mandatory notification of trade by Primary Insiders
Director's Dealing
2022-01-06 English
BerGenBio - Mandatory notification of trade by Primary Insiders
Director's Dealing
2022-01-06 English
BerGenBio - Mandatory notification of trade by Primary Insiders
Director's Dealing
2022-01-06 English